Browsing eNauka
Browsing by Project Novo Nordisk A/S
Showing results 1 to 5 of 5
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2020 | Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A | Tiede, Andreas; Rosa, Cid Ana; Goldmann, Georg; Jimenez-Yuste, Victor; Pluta, Michael; Lissitchkov, Toshko; May, Marcus; Matytsina, Irina; Miljic, Predrag S; Pabinger, Ingrid;
Persson, Paula;
| Article | 21aM21a |
| 2009 | Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial | Russell-Jones, D; Vaag, A; Schmitz, O; Sethi, BK; Lalic, Nebojsa M; Antic, Slobodan S; Zdravkovic, M; Ravn, GM; Simo, R | Article | 21aM21a |
| 2018 | Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial | Lentz, Steven R; Janic, Dragana M   ; Kavakli, Kaan; Miljic, Predrag S ; Oldenburg, Johannes; Ozelo, Margareth Castro; Santagostino, Elena; Suzuki, Takashi; Zupancic-Salek, Silva; Korsholm, Lars;
Matytsina, Irina; Tiede, Andreas;
| Article | 21M21 |
| 2009 | Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT | Strojek, Krzysztof; Bebakar, Wan MW; Khutsoane, Duma T; Pesic, Milica M ; Smahelova, Alena; Thomsen, Henrik F; Kalra, Sanjay | Article | 21M21 |
| 2018 | Use of turoctocog alfa for less-frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in Guardian (TM) 2 | Tiede, Andreas; Janic, Dragana M ; Ozelo, M; Santagostino, E; Korsholm, Lars; Matytsina, Irina; Lentz, SR | Conference Paper | Mp. category will be shown later |